- Behçet’s disease treatments, involving corticosteroids, immunosuppressive agents, and newer biologics, are increasingly vital components of managing this chronic, multisystemic autoimmune disorder, which affects various organ systems such as the eyes, skin, blood vessels, and nervous system, due to their ability to control inflammation, reduce flare-ups, and improve patient quality of life
- The escalating demand for Behçet’s disease treatment is primarily fueled by the rising prevalence of autoimmune and rare diseases, growing awareness among healthcare professionals and patients, and continuous advancements in targeted biologic therapies that offer more effective and personalized treatment options
- North America dominates the Behçet’s disease treatment market with the largest revenue share of 40.5% in 2024, characterized by a well-established healthcare infrastructure, high awareness and diagnosis rates, and a strong presence of leading pharmaceutical companies investing in rare disease research and innovative treatment options
- Asia-Pacific is expected to be the fastest growing region in the Behçet’s disease treatment market during the forecast period due to increasing awareness, rising healthcare investments, expanding access to medical services, and a higher disease prevalence particularly across countries along the ancient Silk Road, such as Turkey, Iran, Japan, and China
- Corticosteroids segment dominates the Behçet’s disease treatment market with a market share of 45.5% in 2024, driven by its established role as the primary treatment option to manage acute symptoms and inflammation, combined with its widespread availability, cost-effectiveness, and adaptability to both oral and injectable forms suitable for various clinical settings
